• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Celularity Inc.

    5/15/26 4:30:21 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CELU alert in real time by email
    NT 10-Q 1 formnt10-q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

     

    Commission File Number: 001-38914

     

    NOTIFICATION OF LATE FILING

     

    ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒Form 10-Q
    ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR  

     

    For Period Ended: March 31, 2026

     

    ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q
    ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR
    ☐ Transition Report on Form 11-K  

     

    For the Transition Period Ended: _______________________________________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________

     

    PART I

    REGISTRANT INFORMATION

     

    Full name of registrant Celularity Inc.
    Former name if applicable  
    Address of principal executive office 170 Park Ave
    City, state and zip code Florham Park, NJ 07932

     

     

     

     

     

     

    PART II

    RULE 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III

    NARRATIVE

     

    State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

     

    Celularity Inc. (“Celularity”) will be unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 (the “March 2026 Form 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period. Constraints in Celularity’s liquidity position and financial accounting staffing levels caused a delay in the financial close and reporting process and preparation of the consolidated financial statements. Celularity is working diligently and plans to file the March 2026 Form 10-Q as soon as practicable.

     

    PART IV

    OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    John Sprague   (908)   845-4530
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

     

    ☒ Yes ☐ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☐ Yes ☒ No

     

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    -2-

     

     

    Celularity Inc.

    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Dated: May 15, 2026   /s/ John Sprague
      By: John Sprague
      Title: Acting Chief Financial Officer

     

    -3-

     

    Get the next $CELU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELU

    DatePrice TargetRatingAnalyst
    1/30/2023$5.00 → $1.00Equal-Weight → Underweight
    Morgan Stanley
    12/22/2022Outperform → Perform
    Oppenheimer
    6/22/2022$15.00Buy
    H.C. Wainwright
    4/6/2022$10.00Buy → Hold
    Truist
    1/28/2022$9.00Outperform
    Oppenheimer
    11/24/2021$9.00Equal-Weight
    Morgan Stanley
    10/19/2021$12.00Buy
    Truist Securities
    More analyst ratings

    $CELU
    SEC Filings

    View All

    Celularity Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    6/3/26 5:22:06 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Celularity Inc (0001752828) (Filer)

    5/28/26 4:54:19 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by Celularity Inc.

    NT 10-Q - Celularity Inc (0001752828) (Filer)

    5/15/26 4:30:21 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

    FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC ("Fountain Life"), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsi

    6/4/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Releases CEO Letter to Shareholders

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below. Dear Fellow Shareholders, I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress.

    6/3/26 4:15:00 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity Appoints Rick Gonzalez as Chief Commercial Officer

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti

    6/3/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lim Kok Thay bought $5,331,335 worth of shares (21,410,983 units at $0.25) (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    1/17/24 5:22:20 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hariri Robert J bought $2,984,294 worth of shares (18,422,124 units at $0.16), increasing direct ownership by 182% to 28,570,434 units (SEC Form 4)

    4 - Celularity Inc (0001752828) (Issuer)

    10/10/23 9:48:11 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celularity downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

    1/30/23 7:11:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Celularity downgraded by Oppenheimer

    Oppenheimer downgraded Celularity from Outperform to Perform

    12/22/22 7:40:17 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Celularity with a new price target

    H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00

    6/22/22 7:19:25 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Barach Philip Alan

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:41:27 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Barach Daniele Wolf

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:41:04 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Philip & Daniele Barach Family Trust

    3 - Celularity Inc (0001752828) (Issuer)

    4/24/26 6:40:13 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Leadership Updates

    Live Leadership Updates

    View All

    Celularity Appoints Rick Gonzalez as Chief Commercial Officer

    FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti

    6/3/26 8:00:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NEXGEL Appoints Ian Blackman as Chief Financial Officer

    Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer. Mr. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., ("Celularity")

    4/27/26 9:00:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $CELU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    SC 13D/A - Celularity Inc (0001752828) (Subject)

    3/15/24 5:32:04 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Celularity Inc. (Amendment)

    SC 13G/A - Celularity Inc (0001752828) (Subject)

    2/8/24 6:00:11 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    SC 13D/A - Celularity Inc (0001752828) (Subject)

    1/17/24 5:15:41 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CELU
    Financials

    Live finance-specific insights

    View All

    Celularity Provides Corporate Update

    FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi

    10/22/24 8:30:00 AM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care